1 |
Andrews, P. A. and Howell, S. B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43 (1990)
|
2 |
Cole, S. P., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G., Pharmacological characterization of multidrug resistant MP-transfected human tumor cells. Cancer Res., 54, 5902-5910 (1994)
|
3 |
Dancis, A., Haile, D., Yuan, D. S., and Klausner, R. D., The saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J. Biol. Chem., 269, 25660- 25667 (1994)
|
4 |
Eisses, J. F. and Kaplan, J. H., Molecular characterization of hCtr1, the human copper uptake protein. J. Biol. Chem., 277, 29162-29171 (2002)
DOI
ScienceOn
|
5 |
Fink, D., Aebi, S., and Howell, S.B., The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4, 1-6 (1998)
|
6 |
Gately, D. P. and Howell, S. B., Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer., 67, 1171- 1176 (1993)
DOI
ScienceOn
|
7 |
Giaccone, G., Clinical perspectives on platinum resistance. Drugs, 59, 9-17 (2000)
|
8 |
Guo, Y., Smith, K., Lee, J., Thiele, D. J., and Patris, M. J., Identification of methionine-rich clusters that regulate copperstimulated endocytosis of the human Ctr1 copper transporter. J. Biol. Chem., 279, 17428-17483 (2004a)
DOI
ScienceOn
|
9 |
Guo, Y., Smith, K., and Petris, M. J., Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: Requirement for the extracellular methionine-rich clusters. J. Biol. Chem., 279, 46393-46399 (2004b)
DOI
ScienceOn
|
10 |
Kanzaki, A., Toi, M., Neamati, N., Miyashita, H., Oubu, M., Nakayama, K., Bando, H., Ogawa, K., Mutoh, M., Mori, S., Terada, K., Sugiyama, T., Fukumoto, M., and Takebayashi, Y., Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn. J. Cancer Res., 93, 70-77 (2002)
DOI
|
11 |
Katano, K., Safaei, R., Samimi, G., Holzer, A., Rochdi, M., and Howell, S.B., The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol. Pharmacol., 64, 466-473 (2003)
DOI
ScienceOn
|
12 |
Kuo, Y. M., Zhou, B., Cossco, D., and Gitschier, J., The copper transporter CTR1 provides and essential function in mammalian embryonic development. Proc. Natl. Acad. Sci. U.S.A., 98, 6836-6841 (2001)
|
13 |
Lai, G. M., Ozols, R. F., Young, R. C., and Hamilton, T. C., Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J. Natl. Cancer Inst., 81, 535-539 (1989)
DOI
|
14 |
Lee, J., Prohaska, J. R., Dagenais, S. L., Glover, T. W., and Thiele, D. J., Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene, 254, 87-96 (2000)
DOI
ScienceOn
|
15 |
Lin, X., Okuda, T., Holzer, A., and Howell, S. B., The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 62, 1154–1159 (2002)
DOI
ScienceOn
|
16 |
Ryoyano, A., Fernandez, C., Sancho, P., de Blas, E., and Aller, P., Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J. Biol. Chem., 276, 47105- 17115 (2001)
|
17 |
Lokich, J. and Anderson, N., Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol., 9, 13- 21 (1998)
DOI
ScienceOn
|
18 |
Minamino, T., Tamai, M., Itoh, Y., Tatsumi, Y., Nomura, M., Yokogawa, K., Suzuki, H., Sugiyama, Y., Ohshima, T., and Miyamoto, K., In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT). Jpn. J. Cancer Res., 90, 1171-1178 (1999)
DOI
|
19 |
Okuda, M., Tsuda, K., Masaki, K., Hashimoto, Y., and Inui, K., Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. Toxicol. Lett., 106, 229–235 (1999)
DOI
ScienceOn
|
20 |
Safaei, R. and Howell, S. B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol., 53, 13-23 (2005)
DOI
ScienceOn
|
21 |
Siddik, Z. H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-7279 (2003)
DOI
ScienceOn
|
22 |
Weiss, R. B., and Christian, M. C., New cisplatin analogues in development. Drugs, 46, 360-377 (1993)
DOI
ScienceOn
|
23 |
Yao, K. S., Godwin, A. K., Johnson, S. W., Ozols, R. F., O'Dwyer, P. J., and Hamilton, T. C., Evidence for altered regulation of gamma-glutamylcystein gene expression among cisplatinsensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res., 55, 4367-4374 (1995)
|
24 |
Siddik, Z. H., Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res., 112, 263-284 (2002)
|
25 |
de Jongh, F. E., van Veen, R. N., Veltman, S. J., de Wit, R., van der Burg, M. E., van den Bent, M. J., Planting, A. S., Graveland, W. J., Stoter, G., and Verweij, J., Weekly highdose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer, 88, 1199-1206 (2003)
DOI
ScienceOn
|
26 |
Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M. Kuo, Y. M., Rochdi, M., and Howell, S. B., Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of Copper. Cancer Res., 62, 6559-6565 (2002)
|
27 |
Helleman, J., Burger, H., Hamelers, I. H., Boersma, A. W., de Kroon, A. I., Stoter, G., and Nooter, K., Impaired Cisplatin Influx in an A2780 Mutant Cell Line: Evidence for a Putative, Cis-Configuration-Specific, Platinum Influx Transporter. Cancer Biol. Ther., (2006). In press
|
28 |
Lee, J., Pena, M. M., Nose, Y., and Thiele, D. J., Biochemical characterization of the human copper transporter Ctr1. J. Biol. Chem., 277, 4380-4387 (2002)
DOI
ScienceOn
|
29 |
Valentine, J. S. and Gralla, E. B., Delivering copper inside yeast and human cells. Science, 278, 817-818 (1997)
DOI
ScienceOn
|
30 |
Ichimura, T., Hung, C. C., Yang, S. A., Stevens, J. L., and Bonventre, J. V., Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol., 286, F552-F553 (2004)
DOI
|
31 |
Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Sluiter, W. J., Meersma, G. J., and de Vries, E. G., Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52, 6885-6889 (1992)
|
32 |
Eisses, J. F. and Kaplan, J. H., The mechanism of copper uptake mediated by human CTR1: a mutational analysis. J. Biol. Chem., 280, 37159-37168 (2005)
DOI
ScienceOn
|
33 |
Ikuta, K., Takemura, K., Sasaki, K., Kihara, M., Nishimura, M., Ueda, N., Naito, S., Lee, E., Shimizu, E., and Yamauch, A., Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol. Pharm. Bull., 28, 707-712 (2005)
DOI
ScienceOn
|
34 |
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., and Hamilton, T. C., Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res., 57, 850-856 (1997)
|
35 |
Culotta, V. C., Klomp, L. W., Strain, J., Casareno, R. L., Krems, B., and Gitlin, J. D., The copper chaperone for superoxide dismutase. J. Biol. Chem., 272, 23469-23472 (1997)
DOI
ScienceOn
|
36 |
Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., and Cvitkovic, E., Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer. Ther., 1, 227-235 (2002)
|
37 |
Schroder, C. P., Godwin, A. K., O'Dwyer, P. J., Tew, K. D., Hamilton, T. C., and Ozols, R. F., Glutathione and drug resistance. Cancer Invest., 14,158-168 (1996)
DOI
|
38 |
Jansen, B. A., Brouwer, J., and Reedijk, J., Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J. Inorg. Biochem., 89, 197-202 (2002)
DOI
ScienceOn
|
39 |
Ishida, S., Lee, J., Thiele, D. J., and Herskowitz, I., Uptake of the anticancer drug cisplatin mediated by copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci., 99, 14298-14302 (2002)
|
40 |
Ludwig, T., Riethmuller, C., Gekle, M., Schwerdt, G., and Oberleithner, H., Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int., 66, 196-202 (2004)
DOI
ScienceOn
|
41 |
Urakami, Y., Okuda, M., Masuda, S., Saito, H., and Inui, K., Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther., 287, 800-805 (1998)
|
42 |
Kollmannsberger, C., Nichols, C., and Bokemeyer, C., Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer, 106, 1217-1226 (2006)
DOI
ScienceOn
|
43 |
Sasada, T., Nakamura, H., Ueda, S., Iwata, S., Ueno, M., Takabayashi, A., and Yodoi, J., Secretion of thioredoxin enhznces cellular resistance to cis-diamminedichloroplatinum (II). Antioxid. Redox. Signal., 2, 695-705 (2000)
DOI
ScienceOn
|
44 |
Thadhani, R., Pascual, M., and Bonventre, J. V., Acute renal failure. N. Engl. J. Med., 334, 1448-1460 (1996)
DOI
ScienceOn
|
45 |
Masters, J. R., Thomas, R., Hall, A. G., Hogarth, L., Matheson, E. C., Cattan, A. R., Lohrer, A. R., and Lohrer, H., Sensitivity of testis tumor cells to chemotherapeutic drugs: role of detoxifying pathways. Eur. J. Cancer, 32A,1248-1253 (1996)
|
46 |
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., and Crook, S. T., Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev., 6, 17-39 (1979)
DOI
ScienceOn
|
47 |
Lee, J., Prohaska, J. R., and Thiele, D. J., Essential role for mammalian copper transporter Ctr1 in copper homeostasis ans embryonic development. Proc. Natl. Acad. Sci. U.S.A., 98, 6842-6847 (2001)
|
48 |
Nakayama, K., Kanazaki, A., Ogawa, K., Miyazaki, K., Neamati, N., and Takebayashi, Y., Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP, and BCRP. Int. J. Cancer, 101, 488-495 (2002)
DOI
ScienceOn
|
49 |
Culotta, V. C., Lin, S. J., Schmidt, P., Klomp, L.W., Casareno, R. L., and Gitlin, J., Intracellular pathways of copper trafficking in yeast and humans. Adv. Exp. Med. Biol., 448, 247-254 (1999)
|
50 |
Ishikawa, T. and Ali-Osmann, F., Glutathione-associated cisdiamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem., 268, 20116-20125 (1993)
|
51 |
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., Yang, X. L., Gao, H., Miura, N., Sugiyama, T., and Akiyama, S., Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 60, 1312-1316 (2000)
|
52 |
Puig, S. and Thiele, D. J., Molecular mechanisms of copper uptake and distribution. Curr. Opin. Chem. Biol., 6, 171-180 (2002)
DOI
ScienceOn
|
53 |
Holzer, A. K., Katano, K., Klomp, L. W., and Howell, S. B., Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res., 10, 6744-6749 (2004)
DOI
ScienceOn
|
54 |
Amaravadi, R., Glerum, D. M., and Tzagoloff, A., Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum. Genet., 99, 329-333 (1997)
DOI
|
55 |
Petris, M. J., Smith, K., Lee, J., and Thieles, D. J., Copperstimulated endocytosis and degradation of the human copper transporter, hCtr1. J. Biol. Chem., 278, 9639-9646 (2003)
DOI
ScienceOn
|
56 |
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E., High resistance to cisplatin in human ovarian cancer cells is associated with marked increae of glutathione synthesis. Proc. Natl. Acad. Sci., 89, 3070-3074 (1992)
|
57 |
Samimi, G., Varki, N. M., Wilczynski, S., Safaei, R., Alberts, D. S., and Howell, S. B., Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res., 9, 5853-5859 (2003)
|
58 |
Yonezawa, A., Satohiro, M., Nishihara, K., Yano, I., Katsura, T., and Inui, K. I., Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biolchem. Pharmacol., 70, 1823-1831 (2005)
DOI
ScienceOn
|
59 |
Dedoussis, G. V., and Andrikopoulos, N. K., Glutathionine depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to natural killer cellmediated cells via necrosis rather than apoptosis. Eur. J. Cell. Biol., 89, 608-614 (2001)
|
60 |
Eisses, J. F., Chi, Y., and Kaplan, J. H., Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. J. Biol. Chem., 280, 9635-9639 (2005)
DOI
ScienceOn
|
61 |
Pena, M. J. O., Puig, S., and Thiele, D. J., Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway. J. Biol. Chem., 275, 33244-33251 (2000)
DOI
ScienceOn
|
62 |
Aller, S. G., Eng, E. T., De Feo, C. J., and Unger, V. M., Eukaryotic Ctr copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. J. Biol. Chem., 279, 53435- 53441 (2004)
DOI
ScienceOn
|
63 |
Klomp, L. W., Lin, S. J., Yuan, D. S., Klausner, R. D., Culotta, V. C., and Gitlin, J. D., Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J. Biol. Chem., 272, 9221-9226 (1997)
DOI
ScienceOn
|
64 |
Puig, S., Lee, J., Lau, M., and Thiele, D. J., Biochemical and Genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J. Biol. Chem., 277, 26021-26030 (2002)
DOI
ScienceOn
|
65 |
Dobyan, D. C., Levi, J., Jacobs, C., Kosek, J., and Weiner, M. W., Mechanism of cis-platinum nephrotoxicity. II. Morphologic observations. J. Pharmacol. Exp. Ther., 213, 551–556 (1980)
|
66 |
Mishima, K., Baba, A., Matsuo, M., Itoh, Y., and Oishi, R., Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Rad. Biol. Med., 40, 1564-1577 (2006)
DOI
ScienceOn
|
67 |
Kapp, T., Muller, S., and Gust, R., Dinuclear Alkylamine Platinum( II) Complexes of [1,2-Bis(4-fluorophenyl)ethylenediamine] platinum(II): Influence of Endocytosis and Copper and Organic Cation Transport Systems on Cellular Uptake. Chem. Med. Chem., 1, 560-564 (2006)
DOI
ScienceOn
|
68 |
Klomp, A. E., Juijn, J. A., van der gun, L. T., van den Berg, I. E., Berger, R., and Klomp, L. W., The N-terminus of the human copper transporter 1 (hCTR1) is localized extracellularly, and interacts with itself. Biochem. J., 370, 881-889 (2003)
DOI
ScienceOn
|
69 |
Schondorf, T., Neumann, R., Benz, C., Riffelmann, M., Gohring, U. J., Sartorius, J., von Konig, C. H., Breidenbach, M., Valter, M. M., Hoopmann, M., Di Nicolantonio, F., and Kurbacher, C. M., Cisplatin, doxorubicin and packlitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent Results Cancer Res., 161, 111-116 (2003)
|
70 |
Howell, S. B., Increased expression of ATP7A mediates platinum resistance. Clin. Cancer Res., 10, 4661-4669 (2004)
DOI
ScienceOn
|
71 |
Ikeda, K., Miura, K., Himeno, S., Imura, N., and Naganuma, A., Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol. Cell. Biochem., 219, 51- 56 (2001)
DOI
ScienceOn
|
72 |
Ooi, C. E., Rabinovich, E., Dancis, A., Bonifacino, J. S., and Klausner, R. D., Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO. J., 15, 3515-3523 (1996)
|
73 |
Song, I. S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., and Kuo, M. T., Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatinsensitive and cisplatin-resistant cells. Mol. Cancer Ther., 3, 1543-1549 (2004)
|
74 |
Valko, M., Rhodes, C. J., Moncol, j., Izakovic, M., and Masur, M., Free radicals, metals and antioxidants in oxidative stressinduced cancer. Chemico-Biolog. Inter., 160, 1-40 (2006)
DOI
ScienceOn
|
75 |
Aller, S. G. and Unger, V. M., Projection structure of the human copper transporter CTR1 at 5-A resolution reveals a compact trimer with a novel channel-like architecture. Proc. Natl. Acad. Sci., 103, 3627-3632 (2006)
|
76 |
Pufahl, R. A., Singer, C. P., Peariso, K. L., Lin, S. J., Schmidt, P. J., Fahrni, C. J., Culotta, V. C., Penner-Hahn, J. E., and O'Halloran, T. V., Metal ion chaperone function of the soluble Cu(I) receptor Atox1. Science, 278, 853-856 (1997)
DOI
|
77 |
Beretta, G. L., Gatti, L., Tinelli, S., Corna. E., Colangelo, D., Zunino, F., and Perego, P., Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem. Pharmacol., 68, 283-291 (2004)
DOI
ScienceOn
|